English
Home
About CPF
About Us
CPF R&D
Factory Style
Video
Products
FAQs
News
Company News
Industry News
Contact Us
Home
Products
U
Ubrogepant
Short Description:
API’s Name
CAS No.
US DMF
EU DMF
Patent Expiry Date( U.S)
Ubrogepant
1374248-77-7
Dec, 2027
Sep.28, 2035
[Indication]
For the acute treatment of migraine with or without aura in adults.
Send email to us
Product Detail
Product Tags
Previous:
Remibrutinib
Next:
1374248-77-7
Ubrogepant
Ubrogepant Chinese
Ubrogepant Chinese GMP factory
Ubrogepant Chinese manufacture
Ubrogepant Chinese supplier
Write your message here and send it to us
Products categories
Pomalidomide
Vibegron (CAS: 1190389-15-1)
Relugolix
Atorvastatin Calcium
Relugolix 737789-87-6
Tirzepatide (CAS: 2023788-19-2)
Hit enter to search or ESC to close